JP Morgan sets $12 price target on Prelude Therapeutics
JP Morgan announced a $12.00/share price target for Prelude Therapeutics, per Benzinga’s ratings actions (via TradingView News).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.